TERT promoter mutations could indicate poor prognosis in glioblastoma

Nature Reviews Neurology

Volumn 10, Issue 10, 2014, Pages 546-

  Malkki, Hemi ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ISOCITRATE DEHYDROGENASE 1; TELOMERASE REVERSE TRANSCRIPTASE; TEMOZOLOMIDE;

CANCER CHEMOTHERAPY; CANCER GRADING; CANCER PROGNOSIS; CANCER SURGERY; CANCER SURVIVAL; CLINICAL PRACTICE; EGFR GENE; ENZYME ACTIVITY; GENE AMPLIFICATION; GENE MUTATION; GENETIC ASSOCIATION; GLIOBLASTOMA; HUMAN; IDH1 GENE; MUTATIONAL ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROMOTER REGION; SHORT SURVEY; TERT GENE;

EID: 84926520316     PISSN: 17594758     EISSN: 17594766     Source Type: Journal    
DOI: 10.1038/nrneurol.2014.168     Document Type: Short Survey

References (2)

1. Labussière, M. et al. Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes. Neurology doi:10.1212/WNL.0000000000000814
2. Simon, M. et al. TERT promoter mutations: a novel independent prognostic factor in primary glioblastomas. Neuro Oncol. doi:10.1093/neuonc/nou158